drugset

drugset / Trial / NCT00129571

Study of XL820 in Adults With Solid Tumors

NCT00129571 ↗

Phase 1 Completed Exelixis

Non-randomizedOpen-labelTreatment

Summary

The purpose of this study is to assess the safety and tolerability of XL820 when given orally to adults with advanced solid tumors.

Timeline

Start: 2005-08
Primary completion: —
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	XL820	Unknown	—	Oral

Indications